# Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients

> **NCT00434590** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Enteric coated mycophenolate sodium (Myfortic®)

## Key facts

- **NCT ID:** NCT00434590
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study has been stopped because of the lack of enrollment
- **Last updated:** 2011-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434590, "Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00434590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*